Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

被引：0

作者：

Cole, Frances M. ^{[1
]}

Laszlo, George S. ^{[2
]}

Lunn-Halbert, Margaret C. ^{[1
]}

Kehret, Allie R. ^{[1
]}

Zweidler-McKay, Patrick A. ^{[3
]}

Rodriguez-Arboli, Eduardo ^{[1
,4
]}

Wu, David ^{[5
]}

Nyberg, Kyle E. ^{[1
]}

Li, Junyang ^{[1
]}

Lim, Sheryl Y. T. ^{[1
]}

Lakshmikanthan, Sribalaji ^{[3
]}

Walter, Roland B. ^{[6
,7
,8
]}

机构：

[1] Fred Hutchinson Canc Ctr, Translat Sci & Therapeut Div, Seattle, WA USA

[2] Fred Hutchinson Canc Ctr, 1100 Fairview Ave North, Seattle, WA USA

[3] ImmunoGen Inc, Waltham, MA USA

[4] Univ Seville, Hosp Univ Virgen del Rocio, Dept Hematol, Inst Biomed Sevilla, Seville, Spain

[5] Univ Washington, Hematopathol, Seattle, WA USA

[6] Fred Hutchinson Canc Ctr, Seattle, WA USA

[7] Univ Washington, Dept Med, Div Hematol & Oncol, Seattle, WA USA

[8] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200907

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2751 / 2751

页数：1

共 50 条

[21] A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Daver, Naval
Sweet, Kendra L.
Montesinos, Pau
Wang, Eunice S.
Aribi, Ahmed
DeAngelo, Daniel J.
Erba, Harry P.
Martinelli, Giovanni
Walter, Roland P.
Altman, Jessica K.
Advani, Anjali S.
Curti, Antonio
Sloss, Callum M.
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
BLOOD, 2020, 136
[22] A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
Daver, Naval Guastad
Montesinos, Pau
Altman, Jessica K.
Advani, Anjali S.
Wang, Eunice S.
Garciaz, Sylvain
Martinelli, Giovanni
Roboz, Gail J.
Walter, Roland B.
Begna, Kebede
Lunghi, Monia
Platzbecker, Uwe
Vyas, Paresh
Burke, Patrick William
Curti, Antonio
DeAngelo, Daniel J.
Gastaud, Lauris
Schliemann, Christoph
Oshrine, Benjamin
Sallman, David Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
Adams, Sharlene
Wilhelm, Alan
Harvey, Lauren
Bai, Chen
Yoder, Nicholas
Kovtun, Yelena
Chittenden, Thomas
Pinkas, Jan
BLOOD, 2016, 128 (22)
[24] Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)
Han, Yoon-Chi
Jiang, Fan
Piche-Nicholas, Nicole
Katragadda, Madan
Prashad, Nadira
Charati, Manoj
Hu, Wendy
Leal, Mauricio
Tumey, Nathan
Maderna, Andreas
Dushin, Russell
Kim, Kenny
Lemon, LuAnna
Damelin, Marc
Gerber, H. P.
Tchistiakova, Lioudmila
Loganza, Frank
O'Donnell, Chris
Sapra, Puja
CANCER RESEARCH, 2018, 78 (13)
[25] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen
Martinelli, Giovanni
Todisco, Elisabetta
Lane, Andrew A.
Acuna-Cruz, Evelyn
Deconinck, Eric
Wang, Eunice S.
Sweet, Kendra L.
Rizzieri, David A.
Mazzarella, Luca
DeAngelo, Daniel J.
Montesinos, Pau
Tarella, Corrado
Erba, Harry P.
Konopleva, Marina
Kantarjian, Hagop M.
Sloss, Callum M.
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
Daver, Naval
BLOOD, 2020, 136
[26] A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Daver, Naval G.
Erba, Harry P.
Papadantonakis, Nikolaos
DeAngelo, Daniel J.
Wang, Eunice S.
Konopleva, Marina Y.
Sloss, Callum M.
Culm-Merdek, Kerry
Zweidler-McKay, Patrick A.
Kantarjian, Hagop M.
BLOOD, 2018, 132
[27] Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
Daver, Naval
Montesinos, Pau
Aribi, Ahmed
Martinelli, Giovanni
Altman, Jessica K.
Wang, Eunice S.
Roboz, Gail J.
Burke, Patrick W.
Gaidano, Gianluca
Walter, Roland B.
Thomas, Xavier
Jeyakumar, Deepa
DeAngelo, Daniel J.
Erba, Harry P.
Todisco, Elisabetta
Begna, Kebede
Advani, Anjali
Gastaud, Lauris
de la Fuente, Adolfo
Curti, Antonio
Mendez, Lourdes M.
Vyas, Paresh
Boissel, Nicolas
Vey, Norbert
Recher, Christian
Longval, Thomas
Platzbecker, Uwe
Kapp-Schworer, Silke
Schliemann, Christoph
Konopleva, Marina
Torres, Laura
Sallman, David A.
Marcucci, Guido
Marconi, Giovanni
Kantarjian, Hagop
Sloss, Callum M.
Malcolm, Karen E.
Zweidler-McKay, Patrick A.
Sweet, Kendra
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S231 - S232
[28] A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Daver, Naval Guastad
Montesinos, Pau
DeAngelo, Daniel J.
Wang, Eunice S.
Todisco, Elisabetta
Tarella, Corrado
Martinelli, Giovanni
Erba, Harry Paul
Deconinck, Eric
Sweet, Kendra L.
Walter, Roland B.
Levy, Moshe Yair
Pemmaraju, Naveen
Lane, Andrew A.
Rizzieri, David
Konopleva, Marina
Sloss, Callum Mortimer
Wang, Jiuzhou
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Daver, Naval G.
Montesinos, Pau
DeAngelo, Daniel J.
Wang, Eunice S.
Papadantonakis, Nikolaos
Deconinck, Eric
Erba, Harry P.
Pemmaraju, Naveen
Lane, Andrew A.
Rizzieri, David A.
Sweet, Kendra L.
Martinelli, Giovanni
Tarella, Corrado
Todisco, Elisabetta
Konopleva, Marina Y.
Sloss, Callum M.
Culm-Merdek, Kerry
Zweidler-McKay, Patrick A.
Kantarjian, Hagop M.
BLOOD, 2019, 134
[30] Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models
Kuruvilla, Vinitha Mary
Zhang, Qi
Daver, Naval
Watkins, Krystal
Sloss, Callum M.
Zweidler-McKay, Patrick A.
Romanelli, Angela
Konopleva, Marina
BLOOD, 2020, 136

← 1 2 3 4 5 →